Keith N. Fargo, Ph.D., is director of scientific programs & outreach at the Alzheimer’s Association. He oversees the Alzheimer’s Association TrialMatch® program, a service that connects people living with Alzheimer’s disease and other dementias, their caregivers, friends and family, and other interested individuals with ongoing clinical studies in their area. Dr. Fargo is responsible for ensuring the quality and responsiveness of TrialMatch, and for educating a wide variety of audiences about the program’s benefits and importance in the fight against Alzheimer’s.
Dr. Fargo coordinates the scientific programming for the Alzheimer’s Association International Conference (AAIC). Annually bringing together thousands of scientists and clinicians from around the globe, AAIC is the world’s largest and most impactful Alzheimer’s and dementia research forum. Dr. Fargo also manages the Alzheimer’s Association’s publication of Alzheimer’s Disease Facts and Figures, a statistical resource for U.S. data related to Alzheimer’s and other dementias. Each annual update reports on the number of people with Alzheimer’s, its cost to society, and a variety of other measures revealing the impact of the disease.
The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) is another element of Dr. Fargo’s day-to-day responsibilities. ISTAART is the professional society of the Alzheimer’s Association, representing scientists, physicians and other professionals active in dementia research. ISTAART facilitates networking and collaboration among its members in order to increase the rate of progress of Alzheimer’s and dementia research.
Dr. Fargo received his Ph.D. from Indiana University and completed a postdoctoral fellowship at Loyola University Stritch School of Medicine. Before joining the Alzheimer’s Association, Dr. Fargo was a researcher with a focus on regenerative processes in the nervous system; he held appointments as a research scientist at the Edward Hines, Jr. VA Hospital Rehabilitation Research & Development Program and as an assistant research professor at the Loyola University Chicago Department of Molecular Pharmacology & Therapeutics.